Business line head Thomas Riermeier, said the strategic transformation will unleash innovation and new service potential by creating system solutions partners for the pharmaceutical and biotech industries and will play a role in increasing the division’s share of system solutions from 20 % currently to more than 50 % by 2030.

The Drug Delivery & Products unit, headed by Paul Spencer, focuses on advancing the company’s system solutions for advanced oral and parenteral drug delivery. This includes the portfolio of branded xcipients such as Eudragit and Resomer lipids and lipid nanoparticles (LNPs), with complementary CDMO services from feasibility studies to commercial drug products.

Evonik said the new unit head has been working in the pharmaceutical industry for more than 30 years and has extensive experience in drug delivery and biomaterials.

The new Drug Substance unit led by Dr Stefan Randl, who has headed lprojects to strengthen Evonik’s position in mRNA and gene therapies since 2020, encompasses the custom development and manufacturing organization (CDMO) services for active pharmaceutical ingredients (APIs) and intermediates as well as its portfolio of API products.

With piloting and world-scale facilities in the US and Germany, Evonik supports customers in this field with scale-up from clinical phases to commercial production, including large-scale high potency APIs (HPAPI) and multi-step complex APIs.

Under the leadership of Maximillian Yeh, who was previously responsible for the global sales organization of the Health Care business line, Evonik’s new Health Solutions product line will focus on fast-growing markets. The company said the unit brings together the biopharma solutions, medical device solutions, and advanced food ingredients solutions businesses.

Author: Dede Williams, Freelance Journalist